生存期-话题@MedSci

#生存期#

350篇内容 | 2794人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378308, encodeId=49d113e830898, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, objectType=article, longId=217398, objectId=e57c21e398b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57c21e398b5, replyNumber=0, likeNumber=80, createdTime=2021-09-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57c21e398b5, moduleTitle=J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57c21e398b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378307, encodeId=b6e413e83076a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, objectType=article, longId=217301, objectId=986821e3019a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=986821e3019a, replyNumber=0, likeNumber=103, createdTime=2021-09-20, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=986821e3019a, moduleTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=986821e3019a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378306, encodeId=598813e8306ec, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=J Clin Oncol：肝切除术后进行mFOLFOX6方案辅助化疗可显著延长仅肝转移的结直肠癌患者的无病生存期！, objectType=article, longId=217215, objectId=63bc21e215a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63bc21e215a3, replyNumber=0, likeNumber=69, createdTime=2021-09-18, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63bc21e215a3, moduleTitle=J Clin Oncol：肝切除术后进行mFOLFOX6方案辅助化疗可显著延长仅肝转移的结直肠癌患者的无病生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63bc21e215a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378305, encodeId=777b13e8305b5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！, objectType=article, longId=217100, objectId=dbfb21e1006b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbfb21e1006b, replyNumber=0, likeNumber=60, createdTime=2021-09-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbfb21e1006b, moduleTitle=Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbfb21e1006b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378304, encodeId=84f713e830403, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, objectType=article, longId=217099, objectId=442f21e09939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442f21e09939, replyNumber=0, likeNumber=106, createdTime=2021-09-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442f21e09939, moduleTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=442f21e09939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378303, encodeId=99d713e8303fe, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=J Thromb Haemost：华法林与低分子肝素治疗癌症相关血栓形成的总生存期, objectType=article, longId=217004, objectId=4ec521e004be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ec521e004be, replyNumber=0, likeNumber=73, createdTime=2021-09-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ec521e004be, moduleTitle=J Thromb Haemost：华法林与低分子肝素治疗癌症相关血栓形成的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ec521e004be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378302, encodeId=d8e513e83027d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JNCCN：经肛门直肠全系膜切除术(TaTME) 治疗直肠癌的局部复发和无病生存期:来自国际TaTME注册研究的结果, objectType=article, longId=216818, objectId=d00f21681836, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d00f21681836, replyNumber=0, likeNumber=56, createdTime=2021-09-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d00f21681836, moduleTitle=JNCCN：经肛门直肠全系膜切除术(TaTME) 治疗直肠癌的局部复发和无病生存期:来自国际TaTME注册研究的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d00f21681836)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378301, encodeId=00b313e8301c7, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！, objectType=article, longId=216812, objectId=832d216812a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=832d216812a4, replyNumber=0, likeNumber=62, createdTime=2021-09-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=832d216812a4, moduleTitle=Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=832d216812a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378300, encodeId=0d8813e83005f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, objectType=article, longId=216224, objectId=35e921622426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35e921622426, replyNumber=0, likeNumber=88, createdTime=2021-08-25, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35e921622426, moduleTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35e921622426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378299, encodeId=92cc13e829948, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=J Thorac Oncol：Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期！, objectType=article, longId=215518, objectId=62cd2155186f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62cd2155186f, replyNumber=0, likeNumber=64, createdTime=2021-08-11, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62cd2155186f, moduleTitle=J Thorac Oncol：Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62cd2155186f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378298, encodeId=c57313e8298a9, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Cancer:他汀类药物可以延长 TNBC 女性的生存期吗？, objectType=article, longId=215369, objectId=902121536992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=902121536992, replyNumber=0, likeNumber=61, createdTime=2021-08-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=902121536992, moduleTitle=Cancer:他汀类药物可以延长 TNBC 女性的生存期吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=902121536992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378297, encodeId=193013e829755, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=免疫药物联合化疗，晚期鼻咽癌患者可获更长生存期, objectType=article, longId=213487, objectId=2d6121348ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6121348ebe, replyNumber=0, likeNumber=79, createdTime=2021-07-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6121348ebe, moduleTitle=免疫药物联合化疗，晚期鼻咽癌患者可获更长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6121348ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378296, encodeId=cf0a13e829604, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！, objectType=article, longId=212933, objectId=58b62129339e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b62129339e, replyNumber=0, likeNumber=64, createdTime=2021-06-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b62129339e, moduleTitle=Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b62129339e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378295, encodeId=e2c813e829571, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Radiology:在精准医疗时代，该如何准确预测肺腺癌患者的无病生存期？, objectType=article, longId=212630, objectId=f41d2126302d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f41d2126302d, replyNumber=0, likeNumber=71, createdTime=2021-06-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f41d2126302d, moduleTitle=Radiology:在精准医疗时代，该如何准确预测肺腺癌患者的无病生存期？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f41d2126302d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378294, encodeId=aa0413e8294f1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析, objectType=article, longId=212622, objectId=2be02126223c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be02126223c, replyNumber=0, likeNumber=100, createdTime=2021-06-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be02126223c, moduleTitle=JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be02126223c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378293, encodeId=bf8513e8293ee, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存, objectType=article, longId=212488, objectId=df61212488ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df61212488ed, replyNumber=0, likeNumber=77, createdTime=2021-06-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df61212488ed, moduleTitle=ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df61212488ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378291, encodeId=522c13e829111, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期, objectType=article, longId=212408, objectId=4ea821240891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ea821240891, replyNumber=0, likeNumber=106, createdTime=2021-06-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ea821240891, moduleTitle=ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ea821240891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378292, encodeId=04ff13e8292e1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期, objectType=article, longId=212407, objectId=dc0d21240ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc0d21240ed5, replyNumber=0, likeNumber=111, createdTime=2021-06-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc0d21240ed5, moduleTitle=ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc0d21240ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378290, encodeId=78b013e82905a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=柳叶刀：高滴度恢复期血浆并不能改善COVID-19住院患者的生存期或其他临床结局, objectType=article, longId=212153, objectId=7482212153a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7482212153a4, replyNumber=0, likeNumber=72, createdTime=2021-06-03, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7482212153a4, moduleTitle=柳叶刀：高滴度恢复期血浆并不能改善COVID-19住院患者的生存期或其他临床结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7482212153a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378289, encodeId=9b5213e828932, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, objectType=article, longId=211652, objectId=9a1e21165207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1e21165207, replyNumber=0, likeNumber=96, createdTime=2021-05-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1e21165207, moduleTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a1e21165207)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！

2021-09-23

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期

2021-09-20

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

J Clin Oncol：肝切除术后进行mFOLFOX6方案辅助化疗可显著延长仅肝转移的结直肠癌患者的无病生存期！

2021-09-18

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Clin Cancer Res：乐伐替尼相比安慰剂将中国放射碘难治性甲状腺癌患者的生存期延长了约 6 倍！

2021-09-16

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期

2021-09-16

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

J Thromb Haemost：华法林与低分子肝素治疗癌症相关血栓形成的总生存期

2021-09-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JNCCN：经肛门直肠全系膜切除术(TaTME) 治疗直肠癌的局部复发和无病生存期:来自国际TaTME注册研究的结果

2021-09-09

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：雷莫芦单抗+吉西他滨作为二线疗法可显著延长恶性胸膜间皮瘤患者的生存期！

2021-09-09

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！

2021-08-25

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

J Thorac Oncol：Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期！

2021-08-11

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Cancer:他汀类药物可以延长 TNBC 女性的生存期吗？

2021-08-07

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

免疫药物联合化疗，晚期鼻咽癌患者可获更长生存期

2021-07-01

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！

2021-06-21

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Radiology:在精准医疗时代，该如何准确预测肺腺癌患者的无病生存期？

2021-06-13

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JCO：3期TOURMALINE-MM1试验| 复发/难治性MM患者采用伊沙佐米-来那度胺-地塞米松治疗的总生存期终分析

2021-06-13

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存

2021-06-10

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期

2021-06-08

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期

2021-06-08

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

柳叶刀：高滴度恢复期血浆并不能改善COVID-19住院患者的生存期或其他临床结局

2021-06-03

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期

2021-05-23

科室
- - 订阅+
  - 更多科室
工具
服务